logo
  

Wells Fargo Reportedly Refunding Customers For Pet Insurance And Other Add-ons

Wells Fargo & Co. (WFC) is in the midst of refunding customers for products including pet insurance and legal services that they did not understand or know how to use, The Wall Street Journal reported Thursday, citing people familiar with the matter.

The bank, which is still recovering from a major scandal when it was discovered to have opened more than 3 million accounts without customer knowledge or approval, is refunding tens of millions of dollars for the products, which were added to hundreds of thousands of accounts, said the Journal.

Wells Fargo charged monthly fees for these add-on products that are now being investigated by the Consumer Financial Protection Bureau. The probe is focused on determining whether customers were deceived, were aware of the products and charges and had the ability to cancel them.

Wells Fargo is "reviewing add-on products sold to consumers by the bank or its service providers and if issues are found during this review, we will make things right with customers in the form of refunds or remediation," Wells Fargo spokeswoman Catherine Pulley reportedly said. The bank is "working with our regulators on the ongoing review."

Just last week, the San Francisco-based bank disclosed a $619 million charge in its second-quarter earnings to refund customers who were overcharged in its foreign exchange, wealth-management and auto- and mortgage lending units.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT